Targeted therapies for high-risk leukemia in children have yet to be ... in Immunology and Cancer are working on a large-scale drug discovery project to get there. In the laboratory run by Brian ...

(“Handa”) (6620.TWO) announced that its U.S. subsidiary, Handa Therapeutics, LLC (the “Company”), has acquired PHYRAGO™ (dasatinib) tablets, a U.S. Food and Drug Administration (“FDA”) approved ...

a U.S. Food and Drug Administration ("FDA") approved chronic myeloid leukemia treatment that was developed by Nanocopoeia, LLC. PHYRAGO is the first and only dasatinib product that can be co ...

a U.S. Food and Drug Administration ("FDA") approved chronic myeloid leukemia treatment that was developed by Nanocopoeia, LLC. PHYRAGO™ is the first and only dasatinib product that can be co ...

PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents PHYRAGO™ was granted Orphan-Drug Designation and has ...

For decades, mental health treatment has often followed a linear path: Try one intervention, wait to see if it works, and then try another if it doesn't. This sequential approach can leave ...